Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Garth Powis

Showing results (21-30 of 100) with videos related to

Pageof 10
Sort By:
Cancer Chemotherapy and Pharmacology|November 12, 2010
Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferaseYon Hui Kim, Amy Coon, Amanda F Baker, et al.
Journal of Medicinal Chemistry|December 30, 2003
Cyclodextrin-derived diorganyl tellurides as glutathione peroxidase mimics and inhibitors of thioredoxin reductase and cancer cell growthMichael McNaughton, Lars Engman, Anne Birmingham, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 3, 2023
Pleckstrin Homology [PH] domain, structure, mechanism, and contribution to human diseaseGarth Powis, Emmanuelle J Meuillet, Martin Indarte, et al.
Cancer Research|September 5, 2002
The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesisSarah J Welsh, William T Bellamy, Margaret M Briehl, et al.
Bioorganic & Medicinal Chemistry|November 8, 2003
Thioredoxin reductase and cancer cell growth inhibition by organotellurium compounds that could be selectively incorporated into tumor cellsLars Engman, Nawaf Al-Maharik, Michael McNaughton, et al.
Anti-Cancer Drugs|February 6, 2003
Thioredoxin reductase and cancer cell growth inhibition by organotellurium antioxidantsLars Engman, Nawaf Al-Maharik, Michael McNaughton, et al.
Molecular Cancer Therapeutics|March 18, 2004
Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alphaSarah Welsh, Ryan Williams, Lynn Kirkpatrick, et al.
Archives of Biochemistry and Biophysics|August 18, 2004
Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activityEmmanuelle J Meuillet, Daruka Mahadevan, Margareta Berggren, et al.
Organic & Biomolecular Chemistry|October 22, 2005
Synthesis and biological activity of prodrug inhibitors of the thioredoxin-thioredoxin reductase systemPeter Wipf, Stephen M Lynch, Garth Powis, et al.
Molecular Cancer Therapeutics|March 21, 2006
Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductaseGarth Powis, Peter Wipf, Stephen M Lynch, et al.
Pageof 10

Showing results (21-30 of 100) with videos related to

Sort By:
Pageof 10
Cancer Chemotherapy and Pharmacology|November 12, 2010
Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferaseYon Hui Kim, Amy Coon, Amanda F Baker, et al.
Journal of Medicinal Chemistry|December 30, 2003
Cyclodextrin-derived diorganyl tellurides as glutathione peroxidase mimics and inhibitors of thioredoxin reductase and cancer cell growthMichael McNaughton, Lars Engman, Anne Birmingham, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 3, 2023
Pleckstrin Homology [PH] domain, structure, mechanism, and contribution to human diseaseGarth Powis, Emmanuelle J Meuillet, Martin Indarte, et al.
Cancer Research|September 5, 2002
The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesisSarah J Welsh, William T Bellamy, Margaret M Briehl, et al.
Bioorganic & Medicinal Chemistry|November 8, 2003
Thioredoxin reductase and cancer cell growth inhibition by organotellurium compounds that could be selectively incorporated into tumor cellsLars Engman, Nawaf Al-Maharik, Michael McNaughton, et al.
Anti-Cancer Drugs|February 6, 2003
Thioredoxin reductase and cancer cell growth inhibition by organotellurium antioxidantsLars Engman, Nawaf Al-Maharik, Michael McNaughton, et al.
Molecular Cancer Therapeutics|March 18, 2004
Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alphaSarah Welsh, Ryan Williams, Lynn Kirkpatrick, et al.
Archives of Biochemistry and Biophysics|August 18, 2004
Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activityEmmanuelle J Meuillet, Daruka Mahadevan, Margareta Berggren, et al.
Organic & Biomolecular Chemistry|October 22, 2005
Synthesis and biological activity of prodrug inhibitors of the thioredoxin-thioredoxin reductase systemPeter Wipf, Stephen M Lynch, Garth Powis, et al.
Molecular Cancer Therapeutics|March 21, 2006
Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductaseGarth Powis, Peter Wipf, Stephen M Lynch, et al.
Pageof 10